TransCode Therapeutics

TransCode Launches Strategic Review of Oncology Portfolio

TransCode Launches Strategic Review of Oncology Portfolio

BOSTON – October 29, 2026 -- TransCode Therapeutics (Nasdaq: RNAZ) has opened a formal strategic process that could end in a sale or licensing of its oncology assets, a partnership or a business combination, with lead candidate TTX-MC138 now in Phase 2a development.

Tungsten Advisors to run the process as exclusive financial advisor

The Board of Directors initiated the review to maximize the value of the company and its oncology portfolio. Options include licensing or selling individual assets, development and commercialization partnerships, portfolio transactions and business combinations. TransCode has engaged Tungsten Advisors as exclusive strategic financial advisor.

CEO and Chairman Philippe P. Calais said the process is meant to support continued development of TTX-MC138 while seeking to maximize value for stockholders.

TransCode Therapeutics CFO Tom Fitzgerald Retires, John Tattory Named Interim CFO

TransCode Therapeutics CFO Tom Fitzgerald Retires, John Tattory Named Interim CFO

Boston – September 17, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) said Chief Financial Officer Tom Fitzgerald is retiring, effective immediately, and will be succeeded on an interim basis by John Tattory.

Fitzgerald exits after eight years steering TransCode through IPO and acquisitions

Fitzgerald has served as CFO since July 2018, a tenure spanning the company's initial public offering, the launch of clinical development for lead candidate TTX-MC138, the acquisition of Polynoma, and a license agreement with Oncolytics. He resigns as CFO and as a company director effective immediately but will remain to provide transition services.

Chairman and CEO Philippe P. Calais credited Fitzgerald with keeping the company funded from its early discovery-stage days. "Tom has worked tirelessly to keep us funded and on track," Calais said.